Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: Results of three US multicenter, double-blind trials
L. Laine et al., Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: Results of three US multicenter, double-blind trials, AM J GASTRO, 95(12), 2000, pp. 3393-3398
OBJECTIVES: To determine the efficacy of once-daily esomeprazole plus antib
iotics for eradication of Helicobacter pylori, to assess the effect of anti
biotic resistance on eradication rate, and to define the rate of emergent r
esistance.
METHODS: Three separate randomized trials were performed in H. pylori-posit
ive patients with a duodenal ulcer or history of documented duodenal ulcer
within 5 yrs: 1) esomeprazole (40 mg once daily), amoxicillin (1 g b.i.d.),
and clarithromycin (500 mg b.i.d.; this combination will be referred to as
EAC) versus esomeprazole (40 mg once daily) plus clarithromycin (500 mg tw
ice daily; this combination will be referred to as EC); 2) EAC versus esome
prazole (40 mg once daily; E); and 3) EC versus E. Therapy was given for 10
days. Endoscopy and biopsies for CLOtest, histology, and culture with susc
eptibility testing were done at baseline and 4 wk after completion of thera
py.
RESULTS: Per-protocol and intent-to-treat eradication rates, respectively,
were as follows. For EAC versus EC in study 1 (N = 448), 84 versus 55% and
77 versus 52% (p < 0.001); for EAC versus E in study 2 (N = 98), 85 versus
5% and 78 versus 4% (p < 0.001); for EC versus E in study 3 (N = 66), 50% v
ersus 0 and 46% versus 0 (p < 0.05). The 15% of patients in the combined st
udies with baseline clarithromycin resistance had significantly lower rates
of eradication than those with susceptible strains (EAC: 45 vs. 89%; EC: 1
3 vs. 61%). Emergent resistance was less common after treatment with EAC [2
/6 (33%)] than with EC (23/27 [85%]).
CONCLUSIONS: Ten-day triple therapy with once-daily esomeprazole plus twice
-daily amoxicillin and clarithromycin achieves an eradication rate virtuall
y identical to that of the twice-daily proton pump inhibitor-based triple t
herapies. Baseline clarithromycin resistance, present in 15% of patients, p
redicts a markedly decreased rate. Use of an amoxicillin-containing regimen
may decrease emergence of clarithromycin resistance. (C) 2000 by Am. Cell.
of Gastroenterology.